Effects of novel tacripyrines ITH12117 and ITH12118 on rat vas deferens contractions, calcium transients and cholinesterase activity

European Journal of Pharmacology

Volumn 660, Issue 2-3, 2011, Pages 411-419

  Pereira, Janaína Drawanz ^a   Caricati Neto, Afonso ^a   Miranda Ferreira, Regiane ^a   Smaili, Soraya Shoubi ^a   Godinho, Rosely Oliveira ^a   Rios, Cristobal De Los ^b,c   Léon, Rafael ^f   Villaroya, Mercedes ^b,c   Samadi, Abdelouahid ^b,c   Marco Contelles, José ^b,c   Jurkiewicz, Neide Hyppolito ^a   Garcia, Antonio G ^b,c,d,e   Jurkiewicz, Aron ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b INSTITUTO TEÓFILO HERNANDO   (Spain)

^c UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^d HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^e CSIC   (Spain)

^f UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Acetylcholinesterase; Alzheimer's disease; Calcium channel blocker; Calcium signaling; Cholinesterase blocker; Hybrid antagonist; ITH12117; ITH12118; Rat brain cortex; Rat vas deferens; Tacripyrines

Indexed keywords

ACETYLCHOLINE; ADENOSINE TRIPHOSPHATE; CALCIUM ION; CENTRAL NERVOUS SYSTEM AGENTS; CHOLINESTERASE; ITH 12117; ITH 12118; NIMODIPINE; NORADRENALIN; PHYSOSTIGMINE; TACRINE; TACRINE DERIVATIVE; UNCLASSIFIED DRUG;

ADVERSE DRUG REACTION; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; CONTROLLED STUDY; DEPOLARIZATION; DRUG EFFICACY; DRUG POTENCY; ENZYME ACTIVITY; ENZYME INHIBITION; NONHUMAN; PRIORITY JOURNAL; RAT; SMOOTH MUSCLE CONTRACTION; SMOOTH MUSCLE TONE; VAS DEFERENS;

EID: 79956086520     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2011.03.042     Document Type: Article

References (52)

1. Ales, E., Cano-Abad, M., García, A.G., López, M.G., 2002. Different cellular distribution of calbindin D28k: implications for the cytosolic Ca(2+) and exocytotic signals in single bovine and mouse chromaffin cells. Ann. N.Y. Acad. Sci. 971, 168-170.
2. Alves-Amaral, G., Pires-Oliveira, M., Andrade-Lopes, A.L., Chiavegatti, T., Godinho, R.O., 2010. Gender-related differences in circadian rhythm of rat plasma acetyl- and butyrylcholinesterase: effects of sex hormone withdrawal. Chem. Biol. Interact. 186, 9-15.
3. Anekonda, T.S., Joseph, F., Quinn, J.F., Harris, C., Frahler, K., Teri, L., Wadsworth, T.L., Woltjerc, R.L., 2010. L-type voltage-gated calcium channel blockade with isradipine as a therapeutic strategy for Alzheimer's disease. Neurobiol. Dis. 41, 62-70.
4. Arce, M.P., Rodríguez-Franco, M.I., González-Muñoz, G.C., Pérez, C., López, B., Villarroya, M., López, M.G., García, A.G., Conde, S., 2009. Neuroprotective and cholinergic properties of multifunctional glutamic acid derivatives for the treatment of Alzheimer's disease. J. Med. Chem. 52, 7249-7257.
5. Arias, E., Alés, E., Gabilan, N.H., Cano-Abad, M.F., Villarroya, M., García, A.G., López, M.G., 2004. Galantamine prevents apoptosis induced by beta-amyloid and thapsigargin: involvement of nicotinic acetylcholine receptors. Neuropharmacology 46, 103-114. (Pubitemid 37494744)
6. Arias, E., Gallego-Sandín, S., Villarroya, M., García, A.G., López, M.G., 2005. Unequal neuroprotection afforded by the acetylcholinesterase inhibitors galantamine, donepezil, and rivastigmine in SH-SY5Y neuroblastoma cells: role of nicotinic receptors. J. Pharmacol. Exp. Ther. 315, 1346-1353.
7. Arnal, F., Coté, L.J., Ginsburg, S., Lawrence, G.D., Naini, A., Sano, M., 1990. Studies on new, centrally active and reversible acetylcholinesterase inhibitors. Neurochem. Res. 15, 587-591.
8. Artalejo, A.R., García, A.G., Neher, E., 1993. Small-conductance Ca(2+)-activated K+ channels in bovine chromaffin cells. Pflugers Arch. 423, 97-103.
9. Bartolini, M., Bertucci, C., Cavrini, V., Andrisano, V., 2003. Beta-amyloid aggregation induced by human acetylcholinesterase: inhibition studies. Biochem. Pharmacol. 65, 407-416.
10. Bezprozvanny, I., 2009. Calcium signaling and neurodegenerative diseases. Trends Mol. Med. 15, 89-100.
11. Burnstock, G., 1986. Purines and cotransmitters in adrenergic and cholinergic neurons. Prog. Brain Res. 68, 193-203.
12. Burnstock, G., 1990. Co-transmission. Arch. Int. Pharmacodyn. 304, 7-33.
13. Cano-Abad, M.F., Villarroya, M., García, A.G., Gabilan, N.H., López, M.G., 2001. Calcium entry through L-type calcium channels causes mitochondrial disruption and chromaffin cell death. J. Biol. Chem. 276, 39695-39704.
14. Caricati-Neto, A., Pupo, A.S., Wanderley, A.G., Nuñez-Vergara, M., Ho Jun Ko, I., Jurkiewicz, N.H., Jurkiewicz, A., 1995. Role of the epithelium in the release of contractile agents from the rat vas deferens by clonidine. Ann. N.Y. Acad. Sci. 763, 436-439.
15. Caricati-Neto, A., Abech D'Angelo, L.C., Reuter, H., Jurkiewicz, N.H., Garcia, A.G., Jurkiewicz, A., 2004. Enhancement of purinergic neurotransmission by galantamine and other acetylcholinesterase inhibitors in the rat vas deferens. Eur. J. Pharmacol. 503, 191-201.
16. Carneiro, R.C., Markus, R.P., 1990. Presynaptic nicotinic receptors involved in release of noradrenaline and ATP from the prostatic portion of the rat vas deferens. J. Pharmacol. Exp. Ther. 255, 95-100.
17. Cavalli, A., Bolognesi,M.L., Capsoni, S., Andrisano, V., Bartolini, M.,Margotti, E., Cattaneo, A., Recanatini, M., Melchiorre, C., 2007. A small molecule targeting the multifactorial nature of Alzheimer's disease. Angew. Chem. Int. 46, 3689-3692.
18. Conceição, I.M., Jurkiewicz, A., Fonseca, D.R., Opperman, A.R., Freitas, T.A., Lebrun, I., Carmo, L.G., 2005. Selective release of ATP from sympathetic nerves of rat vas deferens by the toxin TsTX-1 from Brazilian scorpion Tityus serrulatus. Brit. J. Pharmacol. 144, 519-527.
19. Coyle, J., Kershaw, P., 2001. Galantamine, a cholinesterase inhibitor that allosterically modulates nicotinic receptors: effects on the course of Alzheimer's disease. Biol. Psychiatry 49, 289-299. (Pubitemid 32178438)
20. Cummings, J.L., 2004. Treatment of Alzheimer's disease: current and future therapeutic approaches. Rev. Neurol. Dis. 1, 60-69.
21. Driessen, B., Von Kügelgen, I., Starke, K., 1993. Neural ATP release and its alpha2-adrenoceptor-mediated modulation in guinea-pig vas deferens. Naunyn Schmiedebergs Arch. Pharmacol. 348, 358-366.
22. Eglen, R.M., Hedge, S.S., Watson, N., 1996. Muscarinic receptors subtypes and smooth muscle function. Pharmacol. Rev. 48, 531-565.
23. Ellman, G.L., Courtney, K.D., Andres, V., Featherstone, R.M., 1961. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol. 7, 88-95.
24. Elsinghorst, P.W., Cieslik, J.S.,Mohr, K., Tränkle, C., Gütschow, M., 2007. First gallamine-tacrine hybrid: design and characterization at cholinesterases and the M2 muscarinic receptor. J. Med. Chem. 50, 5685-5695.
25. Enz, A., Boddeke, H., Gray, J., Spiegel, R., 1991. Pharmacologic and clinicopharmacologic properties of SDZ ENA 713, a centrally selective acetylcholinesterase inhibitor. Ann. N.Y. Acad. Sci. 640, 272-275.
26. Feldman, H., Gauthier, S., Hecker, J., Vellas, B., Subbiah, P., Whalen, E., 2001. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology 57, 613-620. (Pubitemid 32782987)
27. Freeman, S.E., Dawson, R.M., 1991. Tacrine: a pharmacological review. Prog. Neurobiol. 36, 257-277.
28. Furchgott, R.F., 1970. Pharmacological characteristics of adrenergic receptors. Fed. Proc. 29, 1352-1361.
29. Giacobini, E., Spiegel, R., Enz, A., Veroff, A.E., Cutler, N.R., 2002. Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: correlationwith cognitive benefit. J. Neural Transm. 109, 1053-1065. (Pubitemid 34762344)
30. Goedert, M., Spillantini, M.G., 2006. A century of Alzheimer's disease. Science 314, 777-781.
31. + indicators with greatly improved fluorescence properties. J. Biol. Chem. 260, 3440-3450.
32. Inestrosa, N.C., Álvarez, A., Pérez, C.A., Moreno, R.D., Vicente, M., Linker, C., Casanueva, O.I., Soto, C., Garrido, J., 1996. Acetylcholinesterase accelerates assembly of amyloid-beta-peptides into Alzheimer's fibrils: possible role of the peripheral site of the enzyme. Neuron 16, 881-891. (Pubitemid 26124065)
33. Jurkiewicz, A., Jurkiewicz, N.H., 1976. Dual effect of alpha-adrenoceptor antagonists in rat isolated vas deferens. Br. J. Pharmacol. 56, 169-178.
34. Jurkiewicz, A., Markus, R.P., Picarelli, Z.P., 1975. Effect of full agonists following calcium deprivation in rat vas deferens. Eur. J. Pharmacol. 31, 292-304.
35. Jurkiewicz, A., Jurkiewicz, N.H., Gomes, C.B., Aucélio, J.G., 1977. Pharmacodynamic analysis of the rat isolated vas deferens after transplantation to intestinal wall. J. Pharmacol. Exp. Ther. 203, 112-119.
36. Khachaturian, Z.S., 1994. Calcium hypothesis of Alzheimer's disease and brain aging. Ann. N.Y. Acad. Sci. 747, 1-11.
37. Lorrio, S., Negredo, P., Roda, J.M., García, A.G., López, M.G., 2009. Effects of memantine and galantamine given separately or in association, on memory and hippocampal neuronal loss after transient global cerebral ischemia in gerbils. Brain Res 1254, 128-137.
38. Maelicke, A., Schrattenholz, A., Samochocki, M., Radina, M., Albuquerque, E.X., 2000. Allosterically potentiating ligands of nicotinic receptors as a treatment strategy for Alzheimer's disease. Behav. Brain Res. 113, 199-206.
39. Marco-Contelles, J., León, R., de los Ríos, C., Samadi, A., Bartolini, M., Andrisano, V., Huertas, O., Barril, X., Luque, F.J., Rodríguez-Franco, M.I., López, B., López, M.G., García, A.G., Carreiras, Mdo. C., Villarroya, M., 2009. Tacripyrines, the first tacrinedihydropyridine hybrids as multitarget-directed ligands for the treatment of Alzheimer's disease. J. Med. Chem. 52, 2724-2732.
40. Miranda, H.F., Duran, E., Fernandez, E., Pinardi, G., 1995. Muscarinic receptor subtypes in the bisected vas deferens of the rat. Gen. Pharmacol. 26, 387-391.
41. Ogura, H., Kosasa, T., Kuriya, Y., Yamanishi, Y., 2000. Comparison of inhibitory activities of donepezil and other cholinesterase inhibitors on acetylcholinesterase and butyrylcholinesterase in vitro. Methods Find. Exp. Clin. Pharmacol. 22, 609-613.
42. Perry, E.K., Haroutunian, V., Davis, K.L., Levy, R., Lantos, P., Eagger, S., Honavar, M., Dean, A., Griffiths, M., McKeith, I.G., 1994. Neocortical cholinergic activities differentiate Lewy body dementia from classical Alzheimer's disease. Neuroreport 21, 747-749. (Pubitemid 24133991)
43. Picarelli, Z.P., Hyppolito, N., Valle, J.R., 1962. Synergistic effect of 5-hydroxytryptamine on the response of rats seminal vesicles to adrenaline and noradrenaline. Arch. Int. Pharmacodyn. Ther. 138, 354-363.
44. Racchi, M., Mazzucchelli, M., Porrello, E., Lanni, C., Govoni, S., 2004. Acetylcholinesterase inhibitors: novel activities of old molecules. Pharmacol. Res. 50, 441-451.
45. Rodriguez-Franco, M.I., Fernandez-Bachiller, M.I., Perez, C., Hernandez-Ledesma, B., Bartolome, B., 2006. Novel tacrine - melatonin hybrids as dual-acting drugs for Alzheimer's disease with improved acetylcholinesterase inhibitory and antioxidant properties. J. Med. Chem. 49, 459-462.
46. Santos, M.D., Alkondon, M., Pereira, E.F., Aracava, Y., Eisenberg, H.M., Maelicke, A., Albuquerque, E.X., 2002. The nicotinic allosteric potentiating ligand galantamine facilitates synaptic transmission in the mammalian central nervous system. Mol. Pharmacol. 61, 1222-1234.
47. Sobrado, M., Lopez, M.G., Carceller, F., García, A.G., Roda, J.M., 2003. Combined nimodipine and citicoline reduce infarct size, attenuate apoptosis, and increase bcl-2 expression after focal cerebral ischemia. Neuroscience 118, 107-113. (Pubitemid 36369535)
48. Summers, W.K., Viesselman, J.O., Marsh, G.M., Candelora, K., 1981. Use of THA in treatment of Alzheimer-like dementia: pilot study in twelve patients. Biol. Psychiatry 16, 145-153. (Pubitemid 11186518)
49. Toda, N., Tago, K., Marumoto, S., Takami, K., Ori, M., Yamada, N., Koyama, K., Naruto, S., Abe, K., Yamazaki, R., Hara, T., Aoyagi, A., Abe, Y., Kaneko, T., Kogen, H., 2003. A conformational restriction approach to the development of dual inhibitors of acetylcholinesterase and serotonin transporter as potential agents for Alzheimer's disease. Bioorg. Med. Chem. 11, 4389-4415.
50. Van Rossum, J.M., Van Der Brink, F.G., 1963. Cumulative dose - response curves - I. Introduction to the technique. Arch. Int. Pharmacol. 143, 240-246.
51. Vladimirova, I., Jurkiewicz, N.H., Jurkiewicz, A., 1994. Evidence for participation of nitric oxide in excitatory neurotransmission in rat vas deferens. Life Sci. 55, 1123-1128. (Pubitemid 24278470)
52. Wang, J.M., Sun, C., 2010. Calcium and neurogenesis in Alzheimer's disease. Front. Neurosci. 4, 1-5.